Building a Database to Study Melanoma in Children and Young Adults
Collects records of children and young adults with melanoma to study survival and outcomes.
Plain-language title generated from the registry record
Registry title: Precision Medicine for L/GCMN and Melanoma 1
Key facts
- Where
- Barcelona, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people of any age with melanoma that has been confirmed by a tissue (biopsy) test. It builds a database to study survival and lymph node results in children, teenagers and young adults.
- Age
- Any age.
- Sex
- All sexes can join.
- Disease stage
- Melanoma confirmed by histopathology (tissue examination). No stage is named.
Main reasons for not taking part
- No melanoma diagnosis
- Informed consent not signed
- Records from before 2012
Read by machine on 12 November 2026.
Where in Spain
- Hospital Clínic de Barcelona (Dermatology service)Barcelona, SpainContact: Susana Puig Sardà, PhD, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fundacion Clinic per a la Recerca Biomédica
- Trial code
- NCT06608420
- Record updated
- 28 February 2025
- Original description
The primary objective of this study is to create a highly multidimensional and multicentric database for melanoma that encompasses cohorts of children, adolescent and young adults. This database will be used to perform survival analysis and evaluate sentinel lymph node (SLNB) positivity in CAYA. The secondary objectives to be met are the following:Read full original descriptionShow less
Precision Medicine for L/GCMN and Melanoma 1 (Precis-mel 1)
The primary objective of this study is to create a highly multidimensional and multicentric database for melanoma that encompasses cohorts of children, adolescent and young adults. This database will be used to perform survival analysis and evaluate sentinel lymph node (SLNB) positivity in CAYA. The secondary objectives to be met are the following:
* Adaptation and optimization of algorithms: work on optimizing existing precision medicine algorithms, which are currently being used in adult patient care, for their application within pediatric and young adult populations. * Implementation of transfer learning: given the limitations associated with pediatric and young adult data, the investigators intend to utilize transfer learning techniques. The study will employ a sequential waterfall methodology, whereby machine learning models trained on adult patient data will be fine-tuned using the more limited data from younger cohorts. * Integration of expert medical opinion: to integrate physician's scientific domain knowledge into the decision support system. This will be facilitated through the comprehensive examination of existing literature, as well as the evaluation of variable risk contributions within each patient group. * AI-based prognostic models: to develop artificial intelligence-based models for the quantitative prognosis of melanoma across the three age groups: adults, young adults, and children.
Inclusion: Melanoma patients of any age with histopathological confirmed melanoma.
Exclusion: Records prior to the year 2012 (as data might not accurately reflect current practices and treatment outcomes); Not having a melanoma diagnosis; Not having signed the informed consent.